DevPro Biopharma and Bespak will initiate clinical trials for the Revolutionary New Albuterol Inhaler

As per the reports, DevPro Biopharma and Bespak recently finished the early feasibility studies on DP007. DP007 is a new formulation of albuterol in a pMDI (pressurized metered dose inhaler) that performs well like Ventolin® HFA but with a significant reduction in greenhouse gas emissions. 

DP007 can revolutionize the treatment of respiratory disease by reducing the global warming potential (GWP) impact of albuterol inhalers such as Ventolin, the most commonly prescribed inhaler type globally. Approximately 384 million people are suffering from chronic obstructive pulmonary disease (COPD)all over the world, and nearly 262 million people have asthma. Most patients rely on pMDIs with a high GWP because Hydrofluoroalkane, a significant greenhouse gas, is used as a propellant. These Greenhouse gas emissions pose a severe challenge to minimizing global temperature rise at or below 2°C.

Bespak has developed this innovative formulation under an exclusive agreement with DevPro Biopharma. The new formulation has Honeywell’s Solstice® Air (HFO-1234ze(E) cGMP), which is a hydrofluoroolefin (HFO) propellant having 99.9% less global warming potential than current HFAs. 

DevPro Biopharma is a respiratory-focused clinical development accelerator, and Bespak is a leading contract development and manufacturing organization (CDMO) that produces orally inhaled and nasal drug-device combination products.

Clinical studies are planned to commence at the year-end to fast-track its development because the pharmaceutical industry now focuses on accelerating its transition to sustainable healthcare products.   

The preliminary results of DP007 will be presented on the 18th of May, 2024, at the Respiratory Innovation Summit. The American Thoracic Society (ATS) will host the summit during the 2024 International Conference at the San Diego Convention Center.